EWP
VRTX icon

Engrave Wealth Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Engrave Wealth Partners’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-5,188
Closed -$1.51M – 415
2020
Q2 		$1.51M Buy
+5,188
New +$1.41M 1.34% 18

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Engrave Wealth Partners's VRTX Position: Q3 2020 in Review

Engrave Wealth Partners sold out of Vertex Pharmaceuticals (VRTX) in Q3 2020, closing a stake of 5,188 shares — an estimated $1.51M sold.

Engrave Wealth Partners first reported a position in VRTX in Q2 2020 and held it in 1 quarter. The position peaked at $1.51M in Q2 2020. 951 funds tracked by Wall St. Rank hold VRTX as of Q3 2020.

  • Engrave Wealth Partners reported no remaining Vertex Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Engrave Wealth Partners sold 5,188 Vertex Pharmaceuticals shares in Q3 2020, an estimated $1.51M.
  • Engrave Wealth Partners first reported a position in Vertex Pharmaceuticals in Q2 2020 and held it in 1 quarter.
  • Engrave Wealth Partners's Vertex Pharmaceuticals position peaked at $1.51M in Q2 2020.
  • 951 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2020.

Based on Engrave Wealth Partners's 13F filing for Q3 2020, filed 8 Oct 2020.